Summary
Sixteen patients with advanced squamous cell carcinoma of the head and neck were entered into a phase II trial of Aclacinomycin-A (ACM), 100 mg/M2 administered by brief infusion every three weeks. All patients had received prior radiation therapy and prior non-anthracycline containing chemotherapy. No clinically significant disease regression was observed in fourteen patients having adequate trials. The major toxicity was myelosuppression; leukopenia occurred in 93% of patients. Gastro-intestinal toxicity was mild and included two patients with transient liver function test abnormalities. No antitumor activity was observed in this patient population which was heavily pre-treated and had a median Karnofsky performance status of only 60%. The results of other phase II trials of ACM-A have been similarly disappointing suggesting that it is not a clinically useful agent in the treatment of solid tumors.
Similar content being viewed by others
References
Oki T, Takeuchi T, Oka S, Umezawa H: New anthacycline antibiotic aclacinomycin A: experimental studies and correlation with clinical trials. Rec Res Cancer Res 76:21–40, 1981
Aclacinomycin A: NCI Clinical Brochure, July, 1979
Hori S, Shirai M, Hirano S, Oki T, Inni T, Tsukagoshi S, Ishizuka M, Takenchi T, Umezawa H: Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gann 68:685–690, 1977
Mathe G, Gescher F, Bayssas M, Misset JL, Machover D, Gilma, Delgado M, Riband P, Hoyat M: Aclacinomycin A in acute leukemia and lymphomas. Lancet: Aug. 11, 310–311, 1979
Sakurai M, Sampi K, Hozumi M: Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A. Leukemia Research 72:139–143, 1983
VanEcho DA, Whitacre MY, Aisner J, Applefeld MM, Wiernik PH: Phase I trial of aclacinomycin A. Can Treat Rep 66, 5:1127–1132, 1982
Mathe G, Byassas M, Gouveia J, Dantchev D, Riband P, Machover D, Misset JL, Schwarzenberg L, Jasmin C, Hayat M: Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. Cancer Chemother. Pharmacol. 1, 259–262, 1978
Chiuten DF, Carr DT, Dhingra HM, Murphy WK, Spitzer G, Umsawasdi T, Bodey GP, Valdivieso M: Aclacinomycin-A in metastatic bronchogenic carcinoma. (Abstract) Proc Am Assoc Ca Res. 25:180, 1984
Decker DA, Drelichman A, Opipari MI, Al-Sarraf M: Phase II evaluation of aclacinomycin-A in adenocarcinoma of the kidney. Am J Clin Oncol (CCT) 7:527–528, 1984
Forastiere AA, Budman DR, Richards F, Aisner J, Weinberg V, Wood WC: Phase II Trial of aclarubicin in advanced breast cancer: a cancer and leukemia group B study. Cancer Treat Rep 67:1137–1138, 1983
Kish JA, Al-Sarraf M: Aclacinomycin. Phase II evaluation in advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol (CCT) 7:534–537, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eckenrode, J.L., Wheeler, R.H. & Forastiere, A.A. A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck. Invest New Drugs 3, 389–392 (1985). https://doi.org/10.1007/BF00170763
Issue Date:
DOI: https://doi.org/10.1007/BF00170763